Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01962337
Other study ID # FPA008-001
Secondary ID 2013-003337-15
Status Terminated
Phase Phase 1
First received
Last updated
Start date October 2013
Est. completion date April 2016

Study information

Verified date December 2021
Source Five Prime Therapeutics, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase 1, randomized, double-blind, placebo-controlled study designed in 3 parts to assess the safety, tolerability, and PK of single and multiple ascending doses of FPA008 in adult healthy volunteers (Parts 1 and 2) and adult subjects with active RA (Part 3).


Description:

Approximately 56 healthy volunteers will be enrolled at 1 study center in the Netherlands for Parts 1 and 2, and approximately 39 subjects will be enrolled at up to 6 sites in Central and Eastern Europe for Part 3. Dose escalations in Parts 1 and 2 will be driven by an assessment of the safety profile. Review of safety and PK parameters may inform decisions to add cohorts with intermediate dose levels in order to reach an optimal target exposure.


Recruitment information / eligibility

Status Terminated
Enrollment 66
Est. completion date April 2016
Est. primary completion date April 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years to 70 Years
Eligibility Inclusion Criteria: Part 1 and 2: - Healthy adult male and female subjects between the ages of 21-55 years inclusive. - Subject must be willing to remain in the Clinical Research Unit (CRU) for a minimum of 72 hours after each dose. Part 3: - RA male and female subjects between the ages of 21-70 years inclusive - Evidence of active RA disease - Inadequate response to biologic or non-biologic DMARDs - Subjects will be required to be on background therapy with methotrexate. Exclusion Criteria: Parts 1, 2 and 3: - BMI <18 or >32 kg/m2 - Clinically significant findings in physical exams and laboratory tests at screening and/or baseline - Unwilling to abstain from alcohol for 48 hours prior to study start, during CRU confinement, as applicable, and for 48 hours prior to study visits. - Unwilling to abstain from exercise more strenuous than walking during CRU confinement, as applicable, and for 48 hours prior to study visits. Parts 1 and 2: - Use of any prescription, non-prescription, or herbal medications as well as supplements or vitamins within 4 weeks prior to dosing, unless approved by the Investigator. - Smoking more than 10 cigarettes, or the equivalent, per day. Part 3: - Current or previous history of inflammatory joint disease other than RA - Evidence of extra-articular RA disease or systemic involvement - Currently taking any medications other than those allowed per protocol guidelines - Any surgical procedure including bone or joint surgery within 12 weeks prior to dosing - Use of intra-articular (IA), intramuscular (IM), or IV corticosteroids for RA - Neuropathies and neurovasculopathies - Concomitant use of statins while on study.

Study Design


Intervention

Drug:
FPA008
Infusion
Placebo
Infusion

Locations

Country Name City State
Hungary BIK-Betegápoló Irgalmas rend-Budai Irgalmasrendi Kórház/Polyclinic of the Hospitaller Brothers of St. John of God in Budapest Budapest
Hungary PRA Clinical Unit Budapest
Hungary Drug Research Center Kaposvar
Netherlands PRA Early Development Services Groningen
Poland Oddzial Kliniczny Kliniki Chorób Wewnetrznych Szpitala Uniwersyteckiego w Krakowie Krakow
Poland MedPolina Poznan

Sponsors (1)

Lead Sponsor Collaborator
Five Prime Therapeutics, Inc.

Countries where clinical trial is conducted

Hungary,  Netherlands,  Poland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of adverse events and dose-limiting toxicities of FPA008 administered in healthy volunteers and RA subjects Incidence of all-grade adverse events and dose limiting toxicities (DLT) during the DLT observation period and/or study treatment periods within 4-12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1